BIOCAD was the first Russian company to export medicinal products based on monoclonal antibodies into the far abroad countries. In 2014-15, the company signed over $700mln in export contracts.
At the moment, the company has approximately 1400 employees, almost half of them are research personnel. BIOCAD now operates four production sites in Moscow and St. Petersburg and has opened its offices in the U.S., Brazil, China, India, Singapore, and other countries.
The company maintains control over the full product cycle from R&D to industrial production. The company portfolio has grown to 45 products for the treatment of cancer, HIV, hepatitis, multiple sclerosis, etc. Another 40 products are at their development stage.
In spring 2018, BIOCAD signed an agreement on the implementation of a joint project with the Ministry of Healthcare of Russia involving the construction of Cell Technology Center for Cancer Treatment in St. Petersburg. By 2021, the company intends to build a new complex at the Special Economic Zone Technopolis Moscow. The complex will span over 55,000 sq.m. and accommodate production facilities, labs, and warehouses.